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Purpose: This study was designed to investigate the characteristics of Korean ad-
renomyeloneuropathy (AMN) patients. Materials and Methods: We retrospec-
tively selected 12 Korean AMN patients diagnosed by clinical analysis and in-
creased plasma content of very long chain fatty acids. Results: All 12 patients 
were men. Patient ages at symptom onset ranged from 18 to 55 years. Family his-
tory was positive in two patients. The phenotype distributions consisted of AMN 
without cerebral involvement in seven patients, AMN with cerebral involvement 
in two patients, and the spinocerebellar phenotype in three patients. Nerve conduc-
tion studies revealed abnormalities in four patients and visual evoked tests re-
vealed abnormalities in three patients. Somatosensory evoked potential tests re-
vealed central conduction defects in all of the tested patients. Spinal MRI showed 
diffuse cord atrophy or subtle signal changes in all 12 patients. Brain MRI findings 
were abnormal in six of the nine tested patients. These brain abnormalities reflect-
ed the clinical phenotypes. Mutational analysis identified nine different ABCD1 
mutations in 10 of 11 tested patients. Among them, nine have been previously re-
ported and shown to be associated with various phenotypes; one was a novel mu-
tation. Conclusion: In conclusion, the present study is the first to report on the 
clinical and mutational spectrum of Korean AMN patients, and confirms various 
clinical presentations and the usefulness of brain MRI scan.
Key Words:   Adrenoleukodystrophy, adrenomyeloneuropathy, ataxia, very long 
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INTRODUCTION
Adrenoleukodystrophy (ALD, OMIM# 300100) is a progressive neurodegenera-
tive disease characterized by an accumulation of very long chain fatty acids (VL-
CFA).1,2 Alterations in the ATP-binding cassette subfamily D, member 1 (ABCD1) 
gene result in dysfunction of the ALD protein, which participates in the peroxisom-
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tional Review Board at our institution (IRB Number: 4-2013-
0167). Written informed consent was exempted by the board 
because this was a retrospective study.
Methods
Clinical data were collected from medical records and in-
cluded age of symptom onset, disease duration, family his-
tory, cognition, cranial nerve function, motor function, sen-
sory disturbance, cerebellar function, deep tendon reflex 
and other associated signs, such as urinary disturbances, 
hypoglycemia, low blood pressure and increased skin pig-
mentation. Plasma adrenocorticotropic hormone (ACTH) 
and cortisol concentrations were measured in seven patients. 
Adrenal function was defined as abnormal if the baseline 
cortisol level was less than 10 μg/dL and the baseline plasma 
ACTH level was greater than 100 pg/mL, or if the cortisol 
response to ACTH stimulation test was suboptimal. Addi-
tionally, data were collected to assess damage to the nervous 
system using electrophysiological and radiological studies. 
Electrophysiological studies were performed using stan-
dardized techniques at room temperature. Motor and senso-
ry nerve conduction studies were tested in eleven patients. 
Visual evoked potential tests were performed in seven pa-
tients. Moreover, median and posterior tibial nerve somato-
sensory evoked potential tests were performed in eight and 
12 patients, respectively. Radiological data included spinal 
and brain MRI scans, which were performed in 12 and 10 
patients, respectively. Mutations were identified by direct 
sequencing using a primer set that covered all 10 exons and 
flanking intron regions of the ABCD1 gene as described by 






The clinical spectrum of the patients is summarized in Table 
1. All 12 patients were men and exhibited increased plasma 
VLCFA levels (Supplementary Table 1, only online). Patient 
ages ranged between 19 and 57 years, and age at symptom 
onset ranged between 18 and 55 years. Disease duration 
ranged between 6 months and 7 years. Family history was 
positive in two patients (patient 10 and 12): the nephew on 
the mother’s side of patient 10 was diagnosed with Addison-
only phenotype at the age of seven years. Additionally, even 
though the mother of patient 12 had not complained of any 
al degradation of VLCFAs. The accumulation of VLCFAs 
primarily affects the central nervous system, adrenal cortex 
and testis; nevertheless, its clinical presentation varies great-
ly.3 Cerebral ALD and adrenomyeloneuropathy (AMN) are 
the main phenotypes of ALD, but these two phenotypes re-
vealed distinct clinical and pathologic features. Cerebral 
ALD is usually diagnosed at a young age and is the most se-
vere phenotype, characterized by rapidly progressive in-
flammatory cerebral demyelination. AMN usually appears 
between the ages of 20 and 50 years and presents as a slowly 
progressive non-inflammatory axonopathy that mainly in-
volves the spinal cord and peripheral nerves. However, about 
20% of AMN patients exhibit cerebral demyelinating in-
volvement later in life.4 This risk is associated with early 
onset, usually between 20 and 35 years of age, and decreas-
es after the age of 45 years.5 In addition to the main pheno-
types, Addison-only, spinocerebellar (olivo-ponto-cerebel-
lar) and asymptomatic phenotypes are occasionally reported.6 
Thus, this heterogeneity in clinical presentations makes it dif-
ficult to diagnose ALD. The clinical characteristics of adult-
onset ALD in Koreans have not yet been evaluated, and 
only a few cases have been reported.7-11 Therefore, the pres-
ent study was designed to investigate the characteristics of 
clinical, electrophysiological, radiological and genetic data 




From January 2006 to June 2013, we retrospectively enrolled 
Korean AMN patients treated at four hospitals: Severance 
Hospital, Yonsei University College of Medicine; Mokdong 
Hospital, Ewha Womans University School of Medicine; 
Kangbuk Samsung Hospital, Sungkyunkwan University 
School of Medicine; and the hospital of National Cancer 
Center. For patient selection, patients who fulfilled the two 
following conditions were selected among medical records: 
1) patients with spastic paraparesis and 2) patients with in-
creased plasma VLCFA levels, especially the C26:0/C22:0 
and C24:0/C22:0 ratios. Based on these criteria, we identified 
twelve AMN patients. Nine patients were evaluated at Sever-
ance Hospital, one was evaluated at Mokdong Hospital, one 
was evaluated at Kangbuk Samsung Hospital, and one was 
evaluated at the hospital of National Cancer Center. Patient 7 
was previously reported on in a Korean journal.9 The present 
study was initiated after obtaining approval from the Institu-
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thria, and patient 12 had dysarthria. 
In addition to neurologic deficits, two patients (patients 8 
and 11) reported thin and scanty scalp hair since adoles-
cence. Symptoms of adrenal insufficiency such as increased 
skin pigmentation, hypoglycemia and low blood pressure 
were not described in any of the patients. However, mea-
surement of plasma cortisol and ACTH concentration, as 
well as ACTH stimulation test, revealed abnormal respons-
es in five of seven tested patients.
Table 2 lists the electrophysiological and radiological fea-
tures of twelve Korean AMN patients. Nerve conduction 
studies demonstrated axonal sensorimotor polyneuropathy in 
four of 11 tested patients. Visual evoked potential tests re-
vealed abnormalities in three of seven tested patients. Medi-
an and posterior tibial somatosensory evoked potential tests 
demonstrated central conduction defects in all tested patients. 
On radiological studies, spinal MRI scans revealed diffuse 
cord atrophy and subtle T2 hyperintensity in 10 and two, re-
spectively. However, Brain MRI scans revealed parenchymal 
abnormalities in six of 10 tested patients. These brain abnor-
malities reflected the clinical phenotypes. Among seven 
AMN patients without cerebral involvement, three patients 
showed only T2 high signal intensities in the corticospinal 
tract. Among two patients with cerebral involvement, patient 
8 showed a lesion involving the corticospinal tract, right tem-
poro-occipital subcortex and cerebellum with patchy en-
hancement (Fig. 1A). Patient 9 presented with T2 high sig-
nal intensities in not only the corticospinal tract but also the 
muscle weakness and sensory disturbance, clinical examina-
tion revealed subtle spastic paraparesis and decreased pro-
prioception on her lower extremities. However, we could 
not confirm her disease due to her refusal.
Onset symptoms included lower limb weakness in eleven 
patients and dysarthria in one patient (patient 10). The phe-
notype distributions consisted of AMN without cerebral in-
volvement in seven patients, AMN with cerebral involve-
ment in two patients, and the spinocerebellar phenotype in 
three patients. Among them, three patients (patients 8, 10, 
and 12) were initially misdiagnosed with multiple sclerosis, 
unknown brainstem encephalopathy and spinocerebellar 
ataxia, respectively. This was because patient 8 exhibited 
unilateral lesions in the right cerebellar and temporo-occipi-
tal regions on brain MRI scans (Fig. 1A), patient 10 mainly 
complained of dysarthria, and patient 12 presented with 
prominent cerebellar limb ataxia.
At clinical examination, all 12 patients showed some de-
gree of muscle weakness, increased tendon reflexes, and 
sensory disturbance on the lower extremities. Eight patients 
had urinary disturbance (urgency, retention or incontinence). 
Among two patients with cerebral involvement, patient 8 
demonstrated personality change, visual disturbance and 
dysarthria. Patient 9 reported visual disturbance. Three pa-
tients with cerebellar ataxia exhibited limb ataxia predomi-
nantly in the unilateral arm, even though the affected arms 
did not show any sensory impairment. In addition to cere-
bellar ataxia, patient 10 had memory impairment and dysar-
























Adrenomyeloneuropathy without cerebral involvement
    1 M/25 No 23 No No No No Yes Yes No No N/A
    2 M/57 No 55 No No No No Yes Yes No Yes No
    3 M/38 No 32 No No No No Yes Yes No Yes Yes
    4 M/30 No 23 No No No No Yes Yes No Yes N/A
    5 M/55 No 48 No No No No Yes Yes No Yes N/A
    6 M/19 No 18 No No No No Yes Yes No No N/A
    7 M/28 No 25 No No No No Yes Yes No Yes Yes
Adrenomyeloneuropathy with cerebral involvement
    8 M/38 No 30 Yes No Yes Yes Yes Yes No Yes Yes
    9 M/20 No 18 No No Yes No Yes Yes No Yes N/A
Spinocerebellar phenotype
    10 M/37 Yes 35 No Yes No Yes Yes Yes Yes No No
    11 M/24 No 23 No No No No Yes Yes Yes No Yes
    12 M/38 Yes 36 No No No Yes Yes Yes Yes Yes Yes
FH, family history; N/A, not available.
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Mutational analysis
We identified nine different mutations of the ABCD1 gene 
in 10 of 11 tested patients, but no mutation was found in one 
(Table 3, Fig. 2). Among the nine different mutations, five 
(56%) were missense, two (22%) were frameshift, and two 
(22%) were deletion. Additionally, mutations were identified 
splenium (Fig. 1B). Among three patients with the spino-
cerebellar phenotype, patient 10 was presented with T2 hy-
perintense lesions around the dentate nuclei (Fig. 1C). 
However, even though patient 12 had cerebellar ataxia, brain 
MRI scan revealed only a lesion in the corticospinal tract 
(Fig. 1D).
Table 2. Electrophysiological and Radiological Features of Korean Patients with Adrenomyeloneuropathy
Electrophysiological study Radiological study
NCS VEP MNSEP PTSEP Spine MRI Brian MRI
Adrenomyeloneuropathy without cerebral involvement
    1 SMP N/A CD CD Diffuse cord atrophy N/A
    2 SMP N/A N/A CD Diffuse cord atrophy No parenchymal lesion
    3 Normal Normal CD CD Diffuse cord atrophy No parenchymal lesion
    4 N/A Normal CD CD Diffuse cord atrophy No parenchymal lesion
    5 SMP N/A CD CD Diffuse cord atrophy N/A
    6 Normal N/A CD CD
T2 high signal intensity 
  in the posterior column 
T2 high signal intensities in the corticospinal tract
    7 Normal CD CD CD Diffuse cord atrophy No parenchymal lesion
Adrenomyeloneuropathy with cerebral involvement
    8 Normal CD CD CD Diffuse cord atrophy
The lesion involving the corticospinal tract, 
  right temporo-occipital subcortex and right 
  cerebellum with patchy enhancement
    9 SMP CD N/A N/A
T2 high signal intensity 
  in the corticospinal tract
T2 high signal intensities in the corticospinal 
  tract and splenium
Spinocerebellar phenotype 
    10 Normal Normal CD CD Diffuse cord atrophy T2 high signal intensities around the dentate nuclei
    11 Normal N/A N/A CD Diffuse cord atrophy T2 high signal intensities in the corticospinal tract
    12 Normal Normal N/A CD Diffuse cord atrophy T2 high signal intensities in the corticospinal tract
NCS, nerve conduction study; VEP, visual evoked potential; MNSEP, median nerve sensory evoked potential; PTSEP, posterior tibial sensory evoked poten-
tial; SMP, sensorimotor polyneuropathy; CD, conduction defect; N/A, not available.
Fig. 1. Brain MRI scans of Korean adrenomyeloneuropathy patients. (A) Patient 8 showed T2 hyperintense lesion involving the corticospinal tract, right tem-
poro-occipital subcortex and right cerebellum. (B) Patient 9 showed T2 hyperintense lesions of the splenium and corticospinal tract. (C) Patient 10 showed 
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ity of ALD is an excess of VLCFAs. However, the patho-
genesis and pathophysiology of ALD is very complex and 
not yet completely understood. Nevertheless, neuropatho-
logic study has revealed a fundamental difference between 
AMN and cerebral ALD.16 Additionally, studies have shown 
that the clinical phenotypes thereof are not correlated with 
genotype, even in members of the same family with the 
same mutation.17,18 This suggests that beyond mutations in 
the ABCD1 gene, other genetic, epigenetic or environmen-
tal factors might be associated with the clinical presentation 
of ALD. For the evaluation of nervous system involvement 
in AMN patients, it is known that electrophysiological stud-
ies, especially somatosensory evoked potential testing, are 
powerful modalities.19-21 In regards to radiological study, 
spinal MRI scans usually show nonspecific cord atrophy in 
AMN patients.22 However, brain MRI scan occasionally 
shows abnormal parenchymal lesions. Commonly, a lesion 
in the corticospinal tract, which probably reflects Wallerian 
degeneration, is found in AMN patients.22 Other demyelin-
ating lesions are considered indicative of progression. 
The present study reports that Korean AMN patients show 
in two hot spots: the transmembrane domain (four mutations, 
44%) and the nucleotide binding domain (three mutations, 
30%). Among nine different mutations, eight were previous-
ly reported in the ALD database (http://www.x-ald.nl/).6,13-15 
However, they were associated with not only AMN but also 
childhood cerebral ALD, adult-onset cerebral ALD, and the 
asymptomatic phenotype. Additionally, even though patients 
6 and 8 had the same genotype (c.1679C>T), one did not 
show cerebral involvement and the other showed clinical 
and radiological involvement in the brain. We identified 
one novel duplication (c.277_296dup20) mutation in the 
present study.
DISCUSSION
The present study reported the clinical, mutational, electro-
physiological and radiological aspects of 12 Korean AMN 
patients. Our results were compatible with previously docu-
mented findings of AMN.
It is well known that the principle biochemical abnormal-
Table 3. The Mutational Analysis of Korean Patients with Adrenomyeloneuropathy
Exon Mutation Allele Type Reference
Adrenomyeloneuropathy without cerebral involvement
    1 1 c.479T>C p.Leu160Pro Missense Sutovský, et al.13
    2 3 c.1166G>A p.Arg389His Missense Kok, et al.14
    3 9 c.1970_72del p.Ile657del In-frame deletion Ligtenberg, et al.15
    4 1 c.421G>A p.Ala141Thr Missense Kok, et al.14
    5 Not found
    6 7 c.1679C>T p.Pro560Leu Missense Kemp, et al.6
    7 Not available
Adrenomyeloneuropathy with cerebral involvement
    8 7 c.1679C>T p.Pro560Leu Missense Kemp, et al.6
    9 1 c.225_242del p.Trp77_Leu82del Deletion Lee, et al.9
Spinocerebellar phenotype
    10 1 c.277_296dup20 p.Leu93fs Frameshift Novel
    11 7 c.1661G>A p.Arg554His Missense Kemp, et al.6
    12 IVS1 c.901-1G>A p.Val301fs Frameshift Kemp, et al.6
IVS, intervening sequence.
Fig. 2. Localization of different mutations within the ABCD1 gene in Korean adrenomyeloneuropathy patients. 
c.277_296dup20
c.225_242del c.479T>C c.1166G>A c.1679C>T
c.421G>A c.901-1G>A c.1661G>A c.1970_72del
Transmembrane domain Nucleotide binding domain
1 2 43 5 6 7 8 9 10
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er cohorts. Second, our study was retrospectively designed 
based on chart reviews. Third, we usually performed VL-
CFA analysis on men with spastic paraparesis. We probably 
missed many ALD patients such as symptomatic female 
carriers of ALD and patients with only endocrinological ab-
normalities. Moreover, the mother of patient 12 was thought 
to be a symptomatic female carrier but she refused further 
evaluation. The nephew of patient 10 was diagnosed with an 
Addison-only phenotype. However, we were unable to ob-
tain his medical records. Nevertheless, we did not include 
these two patients in the present study. Fourth, the pathogenic 
mutation was not identified in patient 5. As patient 5 showed 
elevated plasma VLCFA levels with typical clinical features 
of ALD, he was diagnosed with AMN biochemically.29 There 
are two possibilities for the inability to identify the muta-
tion. One explanation could be that patient 5 had large dele-
tions of one or more exons that could not be identified by 
direct sequencing. Another possibility is that the mutational 
analysis failed to identify alterations of the ABCD1 gene 
due to the presence of ABCD1 paralogs on chromosome 
2q11, 10p11, 16p11 and 22q11.12. Actually, we were unable 
to identify the mutation of patient 12 in the first genetic test, 
as well. However, a c.901-1G>A mutation was identified 
after repetitive tests and change of primers. 
In conclusion, the present study is the first to report on 
the clinical and mutational spectrum of Korean AMN pa-
tients, and confirms various clinical presentations and the 
usefulness of brain MRI scan.
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